Video

Multiple Sclerosis AAN Video Highlights

Aaron Miller, MD, Hideki Garren, MD, and Kate Dawson, MD, discuss the top findings for teriflunomide, ocrelizumab, and tecfidera plus tysabri from the The 69th American Academy of Neurology Annual Meeting for patients with multiple sclerosis.

Miller, professor of Neurology and medical director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Hospital in New York, discusses the safety profile of teriflunomide for patients with multiple sclerosis.

Garren, group medical director, Genentech & Roche Pharmaceutical, discusses ocrelizumab (Ocrevus) for relapsing, primary progressive multiple sclerosis.

Dawson, VP, US Medical Biogen, discusses early treatment with tecfidera and tysabri for patients with multiple sclerosis.


Related Videos
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
© 2024 MJH Life Sciences

All rights reserved.